Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2002
10/31/2002US20020160977 Method for selective inactivation of viral replication
10/31/2002US20020160976 Method for selective inactivation of viral replication
10/31/2002US20020160975 IAPX, member of the Inhibitor of Apoptosis Protein (IAP) family; Smac/DIABLO, a mitochondrial protein; polypeptide that binds to IAP
10/31/2002US20020160972 Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers
10/31/2002US20020160971 Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor
10/31/2002US20020160970 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
10/31/2002US20020160969 Nucleosides and oligonucleotides containing boron clusters
10/31/2002US20020160959 Therapeutic compounds for ovarian cancer
10/31/2002US20020160954 Polynucleotides; Interphotoreceptor matrix component (IPMC) gene family; treating eye disorders
10/31/2002US20020160951 Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160915 Altering the ATP gradient across the membrane of a target cell by inhibiting an extracellular phosphatase (ecto-phosphatase) in the target cell
10/31/2002US20020160516 Useful to the pharmaceutical and biotechnology industries
10/31/2002US20020160501 Methods for generating high titer helper-free preparations of released recombinant AAV vectors
10/31/2002US20020160486 Human RNase H1 mutants
10/31/2002US20020160447 Ups (ugc)
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160414 Immune cell cytokine
10/31/2002US20020160410 Amplification of nucleic acids
10/31/2002US20020160388 Compositions and methods relating to lung specific genes and proteins
10/31/2002US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160365 Compositions and methods for the early diagnosis of ovarian cancer
10/31/2002US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002US20020160017 Malaria vaccine
10/31/2002US20020160016 Modified surface antigen
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020160004 Antibodies against flt3-ligand
10/31/2002US20020160003 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
10/31/2002US20020159983 Bioprosthetic heart valves
10/31/2002US20020159981 A cell population cultured ex-vivo in a culture medium under conditions permitting cells of cell population to proliferate and at the same time reducing capacity of cells in utilizing copper, hence expanded yet not further differentiated
10/31/2002US20020159979 Adeno- associated virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to a promoter and polyadenylation sequences
10/31/2002US20020159978 RAAV virion(recominant adeno-associated virus) comprising an AAV-6 capsid, and a heterologous nucleic acid encoding Factor IX operably linked to expression control element, administering virion to a muscle cell
10/31/2002US20020159977 Administering a recombinant adeno-associated virion into human suffering from hemophilia such that factor VIII nuclotide sequence are expressed at a level which provide therapeutically effective amount in the patient
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2483507A1 Enzyme and snp marker for disease
10/31/2002CA2445627A1 Methods of using a hyaluronan receptor
10/31/2002CA2445202A1 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002CA2445179A1 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002CA2444743A1 Viral vectors having reduced virulence
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2429351A1 A novel human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/30/2002EP1252897A1 Drugs for gene therapy
10/30/2002EP1252894A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
10/30/2002EP1252519A2 Methods for detecting cancer of the central nervous system
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002EP1252322A2 Herpes virus strains for gene therapy
10/30/2002EP1252321A1 Replication deficient adenovirus vectors
10/30/2002EP1252310A2 Mlp gene, nucleic acids, polypeptides and the utilization thereof
10/30/2002EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
10/30/2002EP1252308A2 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
10/30/2002EP1252307A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
10/30/2002EP1252306A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
10/30/2002EP1252303A2 Nucleic acids, proteins, and antibodies
10/30/2002EP1252302A2 Nucleic acids, proteins, and antibodies
10/30/2002EP1252300A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
10/30/2002EP1252298A2 Phosphodiesterases
10/30/2002EP1252297A1 Nucleic acids, proteins, and antibodies
10/30/2002EP1252290A1 Nucleic acids, proteins, and antibodies
10/30/2002EP1252289A2 Nucleic acids, proteins, and antibodies
10/30/2002EP1252187A2 Fil-1 theta dnas and polypeptides
10/30/2002EP1252185A1 Nucleic acids, proteins, and antibodies
10/30/2002EP1252182A1 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
10/30/2002EP1252180A2 Virulence genes, proteins, and their use
10/30/2002EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002EP1252176A2 Nucleic acids, proteins, and antibodies
10/30/2002EP1252175A1 Antisense modulation of survivin expression
10/30/2002EP1251872A1 Compositions and methods for treating cell proliferation disorders
10/30/2002EP1251863A1 22 human secreted proteins
10/30/2002EP1251835A2 Closure of bacterial ghosts
10/30/2002EP1011634B1 Preparation of pharmaceutical compositions
10/30/2002EP0954598A4 Screening assay for compounds stimulating somatostatin and insulin production
10/30/2002EP0918509A4 Biocompatible devices with foam scaffolds
10/30/2002CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002CN1377414A Self-cleaving RNA sequences and their use for the control of protein synthesis
10/30/2002CN1377411A BASB 119 polypeptide and polynucleotide from noraxella catarrhalis
10/30/2002CN1377408A The PRV-1 gene and use thereof
10/30/2002CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002CN1093423C Novel brain endotheliai cell protein and methods for its use
10/30/2002CA2383819A1 Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
10/30/2002CA2344208A1 Method
10/29/2002US6472521 Oligonucleotides for the inhibition of human eg5 expression
10/29/2002US6472520 Rat PEG-3 promoter
10/29/2002US6472376 Gene therapy
10/29/2002US6472375 DNA vaccine and methods for its use
10/29/2002US6472374 Endometrial function
10/29/2002US6472212 Methods and compositions for genetically modifying primate bone marrow cells
10/29/2002US6472204 Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains
10/29/2002US6472181 Hybrid matrix implants and explants
10/29/2002US6472172 DNA encoding a novel human inhibitor-of-apoptosis protein
10/29/2002US6472140 α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
10/29/2002US6471990 A dialkylamide glycylspermine; dioctadecylamide glycylspermine particularly preferred to help the gene to be transported into the target cells
10/29/2002US6471968 Multifunctional nanodevice platform
10/29/2002US6471964 Designated as structural protein-1 (sp-1), the isolated sp-1 protein, and use of the nucleic acid and/or protein for diagnostic or vaccine purposes
1 ... 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 ... 870